Switch theme
Sign up to access all valuation multiples
Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer.
2005
27
LTM Revenue $8.5M
LTM EBITDA -$1.2M
$10.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bio-Gate has a last 12-month revenue (LTM) of $8.5M and a last 12-month EBITDA of -$1.2M.
In the most recent fiscal year, Bio-Gate achieved revenue of $8.1M and an EBITDA of -$1.5M.
Bio-Gate expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bio-Gate valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.5M | XXX | $8.1M | XXX | XXX | XXX |
| Gross Profit | $8.5M | XXX | $4.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | -$1.2M | XXX | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | -18% | XXX | XXX | XXX |
| EBIT | -$1.4M | XXX | -$1.8M | XXX | XXX | XXX |
| EBIT Margin | -17% | XXX | -22% | XXX | XXX | XXX |
| Net Profit | -$1.5M | XXX | -$1.8M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bio-Gate's stock price is EUR 1 (or $1).
Bio-Gate has current market cap of EUR 9.9M (or $11.1M), and EV of EUR 9.4M (or $10.6M).
See Bio-Gate trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.6M | $11.1M | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bio-Gate has market cap of $11.1M and EV of $10.6M.
Bio-Gate's trades at 1.3x EV/Revenue multiple, and -7.1x EV/EBITDA.
Equity research analysts estimate Bio-Gate's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Gate has a P/E ratio of -7.5x.
See valuation multiples for Bio-Gate and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.1M | XXX | $11.1M | XXX | XXX | XXX |
| EV (current) | $10.6M | XXX | $10.6M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | -9.1x | XXX | -7.1x | XXX | XXX | XXX |
| EV/EBIT | -7.4x | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.5x | XXX | -6.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBio-Gate's last 12 month revenue growth is 16%
Bio-Gate's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Bio-Gate's rule of 40 is -10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Gate's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bio-Gate and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | -18% | XXX | XXX | XXX |
| EBITDA Growth | -79% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10% | XXX | -2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Gate acquired XXX companies to date.
Last acquisition by Bio-Gate was XXXXXXXX, XXXXX XXXXX XXXXXX . Bio-Gate acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bio-Gate founded? | Bio-Gate was founded in 2005. |
| Where is Bio-Gate headquartered? | Bio-Gate is headquartered in Germany. |
| How many employees does Bio-Gate have? | As of today, Bio-Gate has 27 employees. |
| Is Bio-Gate publicy listed? | Yes, Bio-Gate is a public company listed on MUN. |
| What is the stock symbol of Bio-Gate? | Bio-Gate trades under BIG1 ticker. |
| When did Bio-Gate go public? | Bio-Gate went public in 2006. |
| Who are competitors of Bio-Gate? | Similar companies to Bio-Gate include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bio-Gate? | Bio-Gate's current market cap is $11.1M |
| What is the current revenue of Bio-Gate? | Bio-Gate's last 12 months revenue is $8.5M. |
| What is the current revenue growth of Bio-Gate? | Bio-Gate revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Bio-Gate? | Current revenue multiple of Bio-Gate is 1.2x. |
| Is Bio-Gate profitable? | Yes, Bio-Gate is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Gate? | Bio-Gate's last 12 months EBITDA is -$1.2M. |
| What is Bio-Gate's EBITDA margin? | Bio-Gate's last 12 months EBITDA margin is -14%. |
| What is the current EV/EBITDA multiple of Bio-Gate? | Current EBITDA multiple of Bio-Gate is -9.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
